Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis

Canadian Journal of Surgery

Volumn 55, Issue 1, 2012, Pages 66-69

  Latosinsky, Steve ^b   Berrang, Tanya S ^b   Cutter, C Suzanne ^b   George, Ralph ^b   Olivotto, Ivo ^b   Julian, Thomas B ^b   Hayashi, Allen ^b   Baliski, Christopher ^b   Croshaw, Randall L ^b   Erb, Kathleen M ^b   Chen, Jennifer ^b   Baxter, N N ^b   Brasel, K J ^b   Brown, C J ^b   Chaudhury, P ^b   Cutter, C S ^b   Divino, C M ^b   Dixon, E ^b   Dubois, L ^b   Fitzgerald, G W N ^b   Henteleff, H J A ^b   Kirkpatrick, A W ^b   Latosinsky, S ^b   MacLean, A R ^b   Mastracci, T M ^b   McLeod, R S ^b   Morris, A M ^b   Neumayer, L A ^b   Temple, L K ^b   McKenzie, M E ^a   more..

^a MOUNT SINAI HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863371701     PISSN: 0008428X     EISSN: 14882310     Source Type: Journal    
DOI: 10.1503/cjs.036011     Document Type: Article

References (10)

1. Lin PP, Allison D, Wainstock J, et al. Impact of axillary lymph node dissection on therapy of breast cancer patients. J Clin Oncol 1993;11: 1536-44. (Pubitemid 23228260)
2. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347: 567-75.
3. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006; 98:599-609. (Pubitemid 43904843)
4. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph node resection compared with conventional axillary-lymph node dissection in clinically node-negative patients with breast cancer: overall survival findings from NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010; 11:927-33.
5. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305:569-75.
6. Piaggio G, Elbourne DR, Altman DG, et al.; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement [published erratum in JAMA 2006; 296:1842]. JAMA 2006;295:1152-60. (Pubitemid 43352345)
7. Duric VM, Stockler MR, Heritier S, et al. Patient's preferences for adjuvant chemotherapy in early breast cancer: What makes AC and CMF worthwhile now? Ann Oncol 2005;16:1786-94. (Pubitemid 41631241)
8. Leitch M, McCall L, Beitsch P, et al. Factors influencing accrual to ACOSOG 10011, a randomized phase III trial of axillary dissection vs. observation for sentinel node positive breast cancer. J Clin Oncol 2006; 24(Suppl):601.
9. Whelan TJ, Olivotto IA, Ackerman I, et al. NCIC-CTG MA20: An intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol 2011;29(Suppl):abstr LBA1003.
10. Straver ME, Meijnen P, van Tienhoven G, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol 2010;17:1854-61.